# FDA Approves Mylan ANDA Application Mylan received FDA approval for ANDA218851 on March 5, 2026, expanding the company's generic drug portfolio and positioning it to capture additional market share in a competitive therapeutic segment. The approval enhances Mylan's ability to serve patients with a cost-effective alternative while strengthening its revenue streams in the generic medicines market.